Related Experiment Video
Updated: May 9, 2026
10:59
Human Blastocyst Biopsy and Vitrification
Published on: July 26, 2019
Could time-lapse embryo imaging reduce the need for biopsy and PGS?
1Department of Obstetrics and Gynecology, Center for Reproductive Medicine, University of Michigan, 475 Market Place Bldg 1 Ste B, Ann Arbor, MI, 48108, USA, swainj@med.umich.edu.
Journal of Assisted Reproduction and Genetics
|July 12, 2013
Summary
Embryo morpho-kinetics, using time-lapse imaging, shows promise in predicting chromosomal aneuploidy. However, embryo biopsy with preimplantation genetic testing remains the most reliable method for assessing embryo health.
Area of Science:
- Reproductive biology
- Genetics
- Embryology
Background:
- Assisted reproductive technologies (ART) aim to improve pregnancy outcomes.
- Accurate embryo selection is crucial for successful in vitro fertilization (IVF).
- Chromosomal aneuploidy is a major cause of implantation failure and miscarriage.
Purpose of the Study:
- To review studies on the relationship between embryo morpho-kinetics and chromosomal aneuploidy.
- To assess the potential of time-lapse imaging in identifying chromosomally abnormal embryos.
Main Methods:
- Comprehensive literature search of PubMed and Medline databases.
- Inclusion of relevant peer-reviewed publications and conference proceedings.
- Analysis of studies focusing on embryo morphology, morphokinetics, and aneuploidy detection.
Main Results:
- Time-lapse imaging (morpho-kinetics) shows potential in predicting aneuploidy.
- Early cleavage timings and events post-maternal-zygotic transition may indicate chromosomal abnormalities.
- An IVF selection algorithm using morpho-kinetics improved outcomes in identifying embryos at low risk for aneuploidy.
Conclusions:
- Combining morphologic assessments and developmental timings may enhance aneuploidy prediction.
- Improved prediction could aid in selecting chromosomally normal embryos, boosting ART success.
- Embryo biopsy with preimplantation genetic screening remains the gold standard for aneuploidy assessment.
